prt7732

·Code: PRT7732

prt7732: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.

Development Pipeline (1)

Clinical Trials (1)

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4

NCT06560645·Phase 1·PRLD
Terminated

Frequently asked questions

Who is developing prt7732?

prt7732 is being developed by Prelude Therapeutics Inc.

How many clinical trials involve prt7732?

BioSniper tracks 1 clinical trial involving prt7732.

Get deeper analysis on prt7732

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis